Trials / Conditions / Unresectable Lung Non-Small Cell Carcinoma

Unresectable Lung Non-Small Cell Carcinoma

19 registered clinical trials studyying Unresectable Lung Non-Small Cell Carcinoma — 6 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer Cachexia NCT06073431	University of Rochester	—
Recruiting	A Phase II Trial to Evaluate the Efficiency and Safety of Serplulimab Plus Chemotherapy as Conversion Therapy NCT05837052	Zhejiang University	Phase 2
Recruiting	Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positiv NCT05098210	Fred Hutchinson Cancer Center	Phase 1
Completed	Supportive Care Intervention (ROAR-LCT) for Patients With Stage IIIA, IIIB, and IV Lung Cancer, ROAR-LCT Trial NCT05339022	Ohio State University Comprehensive Cancer Center	N/A
Recruiting	Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Soli NCT05269381	Mayo Clinic	Phase 1 / Phase 2
Active Not Recruiting	Minnelide and Osimertinib for the Treatment of Advanced EGFR Mutated Non-Small Cell Lung Cancer NCT05166616	City of Hope Medical Center	Phase 1
Recruiting	Papaverine in Combination With Chemoradiation for the Treatment of Stage II-III Non-small Cell Lung Cancer NCT05136846	Ohio State University Comprehensive Cancer Center	Phase 1
Recruiting	Adaptive Radiation Planning for the Reduction of Radiation-Induced Toxicity in Patients With Stage II-IV Non-s NCT04751747	Rutgers, The State University of New Jersey	N/A
Active Not Recruiting	NBTXR3 and Radiation Therapy for the Treatment of Inoperable Recurrent Non-small Cell Lung Cancer NCT04505267	M.D. Anderson Cancer Center	Phase 1
Active Not Recruiting	Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standa NCT04092283	National Cancer Institute (NCI)	Phase 3
Active Not Recruiting	Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients With Advanced Non-s NCT03965689	National Cancer Institute (NCI)	Phase 2
Completed	Resiliency Among Older Adults Receiving Lung Cancer Treatment NCT04229381	Ohio State University Comprehensive Cancer Center	N/A
Completed	Testing the Safety of Adding Either Monalizumab (IPH2201) or Oleclumab (MEDI9447) to Durvalumab (MEDI4736) Plu NCT03801902	National Cancer Institute (NCI)	Phase 1
Active Not Recruiting	Ipilimumab and Nivolumab in Combination With Radiation Therapy in Treating Patients With Stage 2-3 Non-small L NCT04013542	M.D. Anderson Cancer Center	Phase 1
Active Not Recruiting	Trametinib and Pembrolizumab in Treating Patients With Recurrent Non-small Cell Lung Cancer That Is Metastatic NCT03225664	M.D. Anderson Cancer Center	Phase 1 / Phase 2
Completed	Platinum Doublet Chemotherapy and Proton Beam Radiation Therapy in Treating Patients With Stage II-III Non-sma NCT03132532	Mayo Clinic	Phase 2
Active Not Recruiting	CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or NCT02955290	Roswell Park Cancer Institute	Phase 1 / Phase 2
Terminated	Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies NCT02706392	Fred Hutchinson Cancer Center	Phase 1
Terminated	Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherap NCT02419495	M.D. Anderson Cancer Center	Phase 1